Advanced Biological Laboratories (ABL), S.A., a Luxembourg-based diagnostics company and leader in virology genotyping, and Mayo Clinic Laboratories have announced a collaboration. The two organizations are working together to develop a clinical test that will detect mutations associated with antiviral resistance in human cytomegalovirus.
Cytomegalovirus (CMV) is a widespread and common virus that infects people of all ages. Once infected, a person retains the virus for life. Most people don’t even know they have CMV because it rarely causes problems in healthy people. However, CMV infection can cause serious health problems for people with a weakened immune system and for unborn babies. A CMV infection can even be fatal.
“This new test will target the specific genes UL54 and UL97 of CMV,” says Chalom Sayada, M.D., Ph.D., CEO of ABL. “It will aid health care providers who are managing patients infected with CMV who have potential drug resistance to antiviral compounds.”
Based on a next-generation sequencing (NGS) method, the assay sequences PCR amplicons of CMV UL54 and UL97. The test is coupled with ABL’s software called DeepChek-CMV, which is used to analyze sequencing data and provide an interpretation of potential drug resistance in cytomegalovirus.
“We are extremely proud to support the development of this lab-developed test through the provision of our DeepChek-CMV software and are hoping to make CMV personalized treatment adaptation a reality for these patients suffering from the CMV infection,” says Dr. Sayada.
Mayo Clinic has a financial interest in the new technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.